Not adding up!

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

10-41

Rank: President [?]

Points: 1511 [?]

Votes: 12 Score: 3.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Not adding up!

posted on Nov 15, 2021 10:37AM

https://www.globenewswire.com/news-release/2021/11/15/2334457/0/en/Zenith-and-Newsoara-Biopharma-Announce-Expanded-Licensing-and-Investment.html

So, why give it away at this price when:

1. You're at the advanced stage of development that you are with ZEN-3694?

2. You are expecting some jaw-dropping numbers over at Resverlogix with regards to the Covid-19 trial?